Beaten down biopharma Lexicon Pharmaceuticals (LXRX +13.7%) perks up on increased volume, bucking the broad market’s sour mood.
Bargain hunters have apparently been spurred into action in response to a modest level of insider buying and positive revisions from certain sell-side shops.
Shares sold off in late July after Sanofi decided to terminate their Zynquista (sotagliflozin) collaboration.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.